01:59

Risk of Second Tumors and T-Cell Lymphoma after CAR-T Cell Therapy

02:54

Perioperative Nivolumab in Resectable Lung Cancer

01:23

[57] Chemoprevention of head and neck cancer with green tea polyphenols

01:46

[55] Perspectives for cancer prevention with natural compounds

02:00

[54] Cancer phase I clinical trials: efficient dose escalation with overdose control

01:17

[53] Flexible Bayesian methods for cancer phase I trials. Dose escalation with overdose control

03:18

[52] EGFR-targeted therapy with C225 and cisplatin in patients with head and neck cancer

04:12

[50] Phase I and pharmacologic study of OSI-774, an EGFR TKI, for advanced solid malignancies

02:17

[49] Targeting EGFR: integration of novel therapeutics in the management of H&N cancer

02:18

[48] activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo

01:43

[47] Requirement of Stat3 but not Stat1 activation for EGFR-mediated cell growth In vitro

04:41

[46] Pharmacokinetics and variability of green tea catechins and EGCG metabolites in humans

03:30

[45] Green tea catechins on prostate cancer prevention in high-grade PIN patients: a 1-year trial

02:07

[44] Hepatotoxicity associated with supplements containing Chinese green tea

01:03

[43] A receptor for green tea polyphenol EGCG

03:35

[42] Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by EGCG

03:09

[41] EGCG decreases VEGF production in h&N and breast cancer cells by innhibiting EGFR pathways

02:15

[40] Inhibition of Tumor Promoter-Induced Cell Transformation by Tea Polyphenols: EGCG & Theaflavins

03:19

[39] EGCG Effects on Growth, EGFR Signaling, Gene Expression & Chemosensitivity in HNSCC Cells

02:51

[38] EGCG blocks HER-2/neu and related pathways in H&N, Breast cancer cells

08:03

[lung] Afatinib vs cisplatin chemo for EGFR+ lung cancer: survival data from LUX-Lung trials

04:26

[stomach] FLOT vs FLOT/TP for HER2+ Esophagogastric Cancer Trial

02:57

[37] EGCG inhibits EGFR signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases

03:40

[36] EGCG inhibit growth and activation of the EGFR and human HER-2 signaling pathways

02:59

[35] Molecular targets of dietary agents for prevention and therapy of cancer

02:46

[34] Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea

01:30

[33] Green tea and its catechins inhibit breast cancer xenografts

02:15

[32] Blocking telomerase by dietary polyphenols, limiting the growth of cancer cells

01:19

[31] Growth inhibition and regression of human prostate and breast tumors in athymic mice by EGCG

02:59

[30] Growth inhibitory and antimetastatic effect of green tea polyphenols on 4T1 cells

02:38

[29] A green tea polyphenol, EGCG, induces apoptosis of human HCC

01:38

[28] The repressive effect of green tea ingredients on APP expression in oral carcinoma cells

02:10

[27] Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions

02:02

[26] Green tea and cancer in humans a review of the literature

01:35

[25] Cancer rates among drinkers of Black tea

03:29

[24] Green tea and risk of breast cancer in Asian Americans

02:59

[23] Influence of drinking green tea on breast cancer

02:27

[22] Cancer preventive effects of drinking green tea among a Japanese population

03:12

[21] Tumor growth inhibition by simultaneously blocking EGFR and COX-2 in a xenograft model

03:23

[20] Simultaneously targeting EGFR-TK and COX-2, an efficient approach to inhibition of sqcc of H&N

01:38

[19] COX-2: a novel molecular target for the prevention and treatment of head and neck cancer

02:32

[18] Inhibition of cox-2 expression An approach to preventing head and neck cancer

02:48

[17] Biochemoprevention for dysplastic lesions of the upper aerodigestive tract

04:02

[16] Combined interferon alfa13 cis retinoic acid and alpha tocopherol in locally advanced

03:41

[15] Randomized phase III trial of low dose isotretinoin for prevention of second primary tumors

02:27

[14] Low dose isotretinoin versus beta carotene to prevent oral carcinogenesis long term follow up

02:49

[13] Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis,1993 NEJM

02:31

[12] 13-cis-retinoic acid in the treatment of oral leukoplakia (1986 NEJM)

05:30

[10] what is HEAD and NECK cancer?

04:43

[11]Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention

03:00

[9] Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib-

04:15

[8] The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial

02:45

[7] Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through-

03:00

[6] simultaneous blocking of EGFR and cyclooxygenase-2 signaling pathway, chemoprevention of HNC

01:53

[5] Cancer prevention with natural compounds

03:26

[4] Oral cancer prevention advances with a translational trial of green tea

03:00

[3] Role of cyclooxygenase 2 in tumor progression

03:14

[2] Synergistic growth inhibition of sqcc of the head and neck by erlotinib and EGCG

02:52

[1] Phase I trial of oral green tea extract in adult patients with solid tumors

02:40

[lung] Selpercatinib 2022, subset analysis of a Global Phase 1/2